original ) (raw )Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
Flavio Solca
Journal of Medicinal Chemistry, 2019
View PDFchevron_right
Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
mahaveer singh
Drug Discovery Today, 2018
View PDFchevron_right
EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives
Mohamed Elkerdawy
EXCLI journal, 2014
View PDFchevron_right
Faculty of 1000 evaluation for Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Gosia Garstka
F1000 - Post-publication peer review of the biomedical literature, 2010
View PDFchevron_right
Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives
Mariam Ghaly
Bioorganic Chemistry, 2020
View PDFchevron_right
[Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)]
Jayalakshmi Sridhar
Gan to kagaku ryoho. Cancer & chemotherapy, 2009
View PDFchevron_right
Noncovalent wild-type-sparing inhibitors of EGFR T790M
Valentina Pirazzoli
Cancer Discovery, 2013
View PDFchevron_right
Abstract 2585: Discovery of a potent covalent mutant-selective EGFR inhibitor - the journey from high throughput screening to EGF816
Matthew McNeill
Cancer Research, 2015
View PDFchevron_right
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
Rossana Berardi
OncoTargets and Therapy, 2013
View PDFchevron_right
Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation
Awwad Radwan
PloS one, 2024
View PDFchevron_right
Recent progress on third generation covalent EGFR inhibitors
B. Murray
View PDFchevron_right
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
Mark Vincent
Frontiers in Oncology, 2017
View PDFchevron_right
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Hailing Jin , Jing Sun
Cancer discovery, 2014
View PDFchevron_right
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Robert Padera
Nature, 2009
View PDFchevron_right
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation
Jeffrey Simard
Cancer research, 2010
View PDFchevron_right
Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs)
Giannis Mountzios
Annals of Translational Medicine
View PDFchevron_right
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
maricla galetti
Current Pharmaceutical Design, 2012
View PDFchevron_right
In vitro and In vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors that are Wild-type Sparing
Mitch Raponi
Molecular Cancer Therapeutics, 2014
View PDFchevron_right
Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer
Sung-Eun Kim
Targeted oncology, 2018
View PDFchevron_right
Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
REVISTA CIENCIAS BIOMEDICAS
Cribado virtual de Análogos de Osimertinib y Dacomitinib con actividad potencial sobre el receptor de factor de crecimiento epidérmico EGFR (MUTACIONES T790M Y L858R) para el tratamiento del cáncer de pulmón no microcítico, 2021
View PDFchevron_right
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Michele Zorzetto
Respiratory Medicine, 2012
View PDFchevron_right
The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic
Deb Ayeni
Cancer cell, 2015
View PDFchevron_right
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
Mitch Raponi
Cancer discovery, 2013
View PDFchevron_right
Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer
Josep Tabernero
2012
View PDFchevron_right
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
jose juarez
Nature, 2016
View PDFchevron_right
Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation
Christine Tam
Journal of Medicinal Chemistry, 2014
View PDFchevron_right
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Robert Padera
Oncogene, 2008
View PDFchevron_right
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer
Paul Bunn
Lung Cancer, 2010
View PDFchevron_right
Development of Targeted EGFR Degradation for Cancer Treatment
V. Sakanyan
2022
View PDFchevron_right
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
Luca Mologni
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
View PDFchevron_right
Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer
Deb Ayeni
Clinical Cancer Research
View PDFchevron_right
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Glenwood Goss
Translational lung cancer research, 2019
View PDFchevron_right
Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor
Ciric To
View PDFchevron_right
Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
Yuyan Bao
Frontiers in Pharmacology, 2020
View PDFchevron_right
Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors
Tarek Mansour
Bioorganic & Medicinal Chemistry Letters, 2019
View PDFchevron_right